Shelf life, stability make postbiotics attractive alternative to probiotics Probiotics, prebiotics, synbiotics we are living in the age of ‘biotics.’ But there’s one that you are likely to start hearing more about: postbiotics.
There’s growing consumer awareness of probiotics and prebiotics, with the terms listed on labels of many foods and supplements and now many countries are increasingly using them for regulation purposes. But the non-viable microorganisms and the metabolites that they produce are still unfamiliar territory for most.
Postbiotics
While there’s no official definition just yet,
“Postbiotics are functional fermentation compounds or let s call the metabolites or waste products of probiotics that can be used in combination with other nutritional components to promote health,” explained Matthew Olesiak, MD, chief medical director at SANESolution.
Pantheryx acquires Bayer’s TruBiotics in effort to accelerate probiotic category Colostrum-based nutrition and biotechnology company Pantheryx has announced that it has acquired probiotic brand TruBiotics and its trademarks from Bayer HealthCare.
The TruBiotics brand will join PanTheryx’s current lineup and ingredient offerings, including Life’s First Naturals, dairy colostrum, and prebiotics. The company said the new addition encompasses a full spectrum of supplements that support digestive and immune health at all stages of life.
“The acquisition of TruBiotics is consistent with our strategy to accelerate growth through acquisitions of synergistic brands in fast-growing strategic categories,” said Wes Parris, president and CEO of PanTheryx.
Supplementing an infant with Bifidobacterium breve CECT7263 may present an “earlier and more robust effect than the reference prescribed drug” for the management of colic, says a new clinical trial.
Ferring Pharmaceuticals, Rebiotix and MyBiotics Pharma are to enter a research collaboration that focuses on live microbiota-based biotherapeutics to address bacterial vaginosis (BV).
The agreement looks to expand on each firms’ expertise in reproductive medicine and women’s health, by creating standardised, stable live microbiota-based formulations addressing the vaginal infection.
Common among women of reproductive age, the condition is linked to an increased risk of miscarriage, as well as problems during pregnancy and fertility issues.
“Today’s agreement is an important evolution of our long-standing relationship with Ferring in the field of microbiota-based therapies for the benefit of women s health, including reproduction and pregnancy,” says MyBiotics’ CEO, David Daboush.